Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | GPR39 | O43194 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390836 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1PLD1PANK3 | |
| Hydrochloric Acid SCHEMBL30731344 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1PLD1PANK3 | |
| Hydrochloric Acid SCHEMBL21521443 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1PLD1PANK3 | |
| Hydrochloric Acid SCHEMBL23302464 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1PLD1PANK3 | |
| Hydrochloric Acid SCHEMBL17455098 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1PLD1PANK3 | |
| SCHEMBL2003952 | 0.94 | KDR (0.50) | KDM4EALDH1A1L3MBTL1PLD1PANK3 | |
| Hydrochloric Acid SCHEMBL31465050 | 0.92 | KDR (0.49) | KDM4EALDH1A1L3MBTL1PLD1PANK3 | |
| SCHEMBL7257034 | 0.90 | KDM4E (0.49) | KDM4EALDH1A1L3MBTL1PANK3GPR119 | |
| SCHEMBL12911541 | 0.87 | GPR119 (0.55) | PLD1GPR119HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL943137 | 0.86 | GPR119 (0.54) | PLD1GPR119HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| US-12384780-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4594314-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | Azkarra Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-120020129-A | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业股份有限公司 | 2025-05-20 | — | — | CN | disclosed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2003087071-A1 | SULFONAMIDE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| CN-1090273-A | Acetogenin | GLAXO GROUP LTD (GB) | 1994-08-03 | — | — | CN | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
| EP-0592949-A2 | N-(aminocarbonyl)-piperidines/pepirazines as aggregation inhibiting agents | Dr. Karl Thomae GmbH (DE) | 1994-04-20 | — | — | EP | disclosed |
| CN-1073169-A | Acetogenin | GLAXO GROUP LTD (GB) | 1993-06-16 | — | — | CN | disclosed |
| EP-0542363-A2 | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | GLAXO GROUP LIMITED (GB) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | KDM4E 2700/4885ALDH1A1 2423/4885L3MBTL1 4177/4885 |
| US-12384780-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | KDM4E 1632/4885ALDH1A1 1913/4885L3MBTL1 1069/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | KDM4E 2514/4885ALDH1A1 1500/4885L3MBTL1 1806/4885 |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | PARP1, PARP11, PARP12 | KDM4E 1388/4885ALDH1A1 1859/4885L3MBTL1 2199/4885 |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | KDM4E 3606/4885ALDH1A1 1213/4885L3MBTL1 523/4885 |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | KDM4E 3408/4885ALDH1A1 401/4885L3MBTL1 4647/4885 |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRD3 | KDM4E 553/4885ALDH1A1 2552/4885L3MBTL1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.